Drugs / tuberculin
tuberculin
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05027958 | May 2022 → Nov 2024 | latent tuberculosis infection | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07072065 | Apr 2022 → Mar 2023 | anogenital human papillomavirus infection | Padjadjaran University | Completed | No outcome recorded |
| Phase 2 | NCT02329730 | Feb → Jun 2014 | tuberculosis | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01798121 | Feb → Mar 2013 | tuberculosis | JHP Pharmaceuticals LLC | Unknown | No outcome recorded |
| Phase 2 | NCT01689831 | May → Oct 2012 | tuberculosis | JHP Pharmaceuticals LLC | Unknown | No outcome recorded |
| Phase 2 | NCT00128193 | Apr 2002 → Sep 2009 | leprosy | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05899179 | Aug 2023 → Jul 2025 | latent tuberculosis infection | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03153566 | Jun 2017 → Jun 2018 | anogenital human papillomavirus infection | Assiut University | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07054697 | Jan 2017 → Dec 2024 | autism spectrum disorder | Aditi Chadha | Completed | No outcome recorded |
| Phase 4 | NCT07161804 | Dec 2016 → Dec 2024 | autism spectrum disorder | Holistic Homoeopathic Clinic and Research Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01242475 Comparator | Apr → Nov 2011 | tuberculosis | Statens Serum Institut | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05254561 Comparator | Nov 2020 → Jun 2021 | — | Zagazig University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04288817 Comparator | Mar 2020 → Mar 2021 | common wart | Assiut University | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03477448 Comparator | Apr 2018 → Apr 2019 | plantar wart | Assiut University | Unknown | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tuberculin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03153566 ↗ |
| Known as | 2 TU Tuberculin PPD RT 23 SSI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01242475 ↗ |
| Known as | Aplisol@ | “Aplisol@ will be compared to reference standard material” NCT01798121 ↗ |
| Known as | PPD | “The primary objective of this study is to understand the pulmonary immune response to mycobacterial antigens by determining the persistence of antigen-specific immune cells in...” NCT05027958 ↗4“Purified protein derivative (PPD) is an extract of Mycobacterium tuberculosis and is used for testing exposure to tuberculin protein, either from a previous vaccination or from...” NCT03477448 ↗ “intralesional purified protein derivative (PPD) in the treatment of RMCW” PMID 23336207 ↗ May 2013 “intralesional purified protein derivative (PPD) immunotherapy” PMID 36705474 ↗ Jan 2023 “purified protein derivative (PPD)” NCT05254561 ↗ |
| Known as | Purified protein derivative | “Purified protein derivative or tuberculin stimulates the cell mediated immunity non specifically by activating T helper 1 cells” NCT03153566 ↗ |
| Known as | Purified Protein Derivative of Tuberculin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05899179 ↗ |
| Known as | Tuberculin ppd | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108161 ↗ |
| Known as | tuberculin purified protein derivative | “tuberculin purified protein derivative with dose 5 tuberculin unit” NCT07072065 ↗ |
| Known as | Tuberculin, old | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108161 ↗ |
| Known as | Tuberculin, purified protein derivative of | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108161 ↗ |
| Known as | TUBERCULINUM | “Thuja officinalis Vaccininum Causticum Argentum nitricum Tuberculinum Stramonium Staphysagria Arum triphyllum Bacillinum Cina Carcinocin Cuprum Metallicum Ambera grisea...” NCT07161804 ↗1“TUBERCULINUM” NCT07054697 ↗ |
| Known as | Tubersol | “Healthy volunteer participants with confirmed Latent Tuberculosis Infection (LTBI) (TST positive and IGRA positive) receiving instillation dose of purified protein derivative...” NCT05027958 ↗1“5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).” NCT00128193 ↗ |
| Modality | Diagnostic / imaging agent | “A tuberculin skin test used to diagnose latent tuberculosis (TB) infection.” NCT00128193 ↗ |
| Route | Other | “given intradermally by the Mantoux technique” NCT01242475 ↗ |